Third-Party Payers’ Class Actions For Alzheimer’s Drugs Survive Dismissal

Mealey's (September 23, 2016, 10:19 AM EDT) -- NEW YORK — A New York federal judge on Sept. 13 left unscathed two third-party payer lawsuits alleging that the maker of the Alzheimer’s drug Namenda pulled their original version of the drug early and forced insurers to pay for a higher-cost follow-on drug (Sergeants Benevolent Association Health & Welfare Fund, et al. v. Actavis, PLC, et al., No. 15-6549, JM Smith Corporation, et al. v. Actavis, PLC, et al., No. 15-7488, S.D. N.Y.; 2016 U.S. Dist. LEXIS 128349).

(Opinion available. Document #28-161006-009Z.)

Forest Laboratories LLC...
To view the full article, register now.